{"schema_version":"secwatch.filing_event.v1","accession":"0001999371-26-005742","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2026-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.065303+00:00","generated_at":"2026-05-15T12:28:36.212217+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tonix reports Q4 2025 net loss $46.9M; TONMYA launch shows ~4,200 prescriptions","bullets":["Net loss available to common stockholders for Q4 2025 was $46.9M ($3.98/share) vs $22.1M ($9.77/share) in Q4 2024.","Full year 2025 net product revenue $13.1M, including TONMYA launch from Nov 17–Dec 31: $1.4M.","TONMYA launch-to-date (Nov 17,2025–Feb 27,2026): >1,500 HCPs prescribed, ~2,500 patients initiated, ~4,200 cumulative prescriptions.","Cash and equivalents $207.6M as of Dec 31, 2025 (up from $98.8M); subsequent ATM raised $8.6M.","Cash runway expected into Q1 2027; shares outstanding 13.4M as of March 11, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001999371-26-005742","json":"https://secwatch.observer/filing/0001999371-26-005742.json","markdown":"https://secwatch.observer/filing/0001999371-26-005742.md","text":"https://secwatch.observer/filing/0001999371-26-005742.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000199937126005742/0001999371-26-005742-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000199937126005742/tonix-8k_031326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T12:28:36.212217+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e511bcb7b5f99e23df98db7c956f96f49f0c10c1","claim":"Tonix Pharmaceuticals Holding Corp. reported financial results for the fourth quarter and full year ended December 31, 2025.","evidence_excerpt":"announced its operating results for the quarter and year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1430306/000199937126005742/0001999371-26-005742-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}